Department of Pathology, University of Saskatchewan and Saskatoon Health Authority, Saskatoon, SK, Canada
CEO and co-Founder, Boston Cell Standards
Chief of Pathology, PreludeDx
Department of Pathology, Isala, Zwolle, Netherlands
Department of Pathology & Laboratory Medicine, New York Presbyterian/Columbia University Irving Medical Center, New York
Associate Professor Pathology and Laboratory Medicine, University Saskatchewan
NYU Langone Health, Director of Histology, Center for Biospecimen Research and Development, New York
Medical Director, Advanced Diagnostic Research Laboratory (ADRL), Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan
BLS NordiQC, Aalborg, DK
FIBMS, Manager and Scientific Lead, UKEQAS, London, UK
Research Department of Pathology, University College London, London, UK
Professor of Pathology, Institute of Cancer & Genetics, Cardiff
University & Associate Postgraduate Dean for Academic Medicine in Wales (2011-2015)
Director of Pathology, Targos Molecular Pathology GmbH, Kassel, Germany (2016 – 2022)
Finding the optimal analytic sensitivity set points for each important IHC assay is a daunting task because there are so many. We can certainly use help:
By Boston Cell Standards | Funded by The National Cancer Institute, National Institutes of Health | Terms & Privacy